Suppr超能文献

院前持续气道正压通气治疗急性呼吸衰竭:ACUTE 可行性 RCT。

Prehospital continuous positive airway pressure for acute respiratory failure: the ACUTE feasibility RCT.

机构信息

Centre for Urgent and Emergency Care Research, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK.

Clinical Trials Research Unit, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK.

出版信息

Health Technol Assess. 2021 Feb;25(7):1-92. doi: 10.3310/hta25070.

Abstract

BACKGROUND

Acute respiratory failure is a life-threatening emergency. Standard prehospital management involves controlled oxygen therapy. Continuous positive airway pressure is a potentially beneficial alternative treatment; however, it is uncertain whether or not this treatment could improve outcomes in NHS ambulance services.

OBJECTIVES

To assess the feasibility of a large-scale pragmatic trial and to update an existing economic model to determine cost-effectiveness and the value of further research.

DESIGN

(1) An open-label, individual patient randomised controlled external pilot trial. (2) Cost-effectiveness and value-of-information analyses, updating an existing economic model. (3) Ancillary substudies, comprising an acute respiratory failure incidence study, an acute respiratory failure diagnostic agreement study, clinicians perceptions of a continuous positive airway pressure mixed-methods study and an investigation of allocation concealment.

SETTING

Four West Midlands Ambulance Service hubs, recruiting between August 2017 and July 2018.

PARTICIPANTS

Adults with respiratory distress and peripheral oxygen saturations below the British Thoracic Society's target levels were included. Patients with limited potential to benefit from, or with contraindications to, continuous positive airway pressure were excluded.

INTERVENTIONS

Prehospital continuous positive airway pressure (O-Two system, O-Two Medical Technologies Inc., Brampton, ON, Canada) was compared with standard oxygen therapy, titrated to the British Thoracic Society's peripheral oxygen saturation targets. Interventions were provided in identical sealed boxes.

MAIN OUTCOME MEASURES

Feasibility objectives estimated the incidence of eligible patients, the proportion recruited and allocated to treatment appropriately, adherence to allocated treatment, and retention and data completeness. The primary clinical end point was 30-day mortality.

RESULTS

Seventy-seven patients were enrolled (target 120 patients), including seven patients with a diagnosis for which continuous positive airway pressure could be ineffective or harmful. Continuous positive airway pressure was fully delivered to 74% of participants (target 75%). There were no major protocol violations/non-compliances. Full data were available for all key outcomes (target ≥ 90%). Thirty-day mortality was 27.3%. Of the 21 deceased participants, 14 (68%) either did not have a respiratory condition or had ceiling-of-treatment decision implemented that excluded hospital non-invasive ventilation and critical care. The base-case economic evaluation indicated that standard oxygen therapy was probably cost-effective (incremental cost-effectiveness ratio £5685 per quality-adjusted life-year), but there was considerable uncertainty (population expected value of perfect information of £16.5M). Expected value of partial perfect information analyses indicated that effectiveness of prehospital continuous positive airway pressure was the only important variable. The incidence rate of acute respiratory failure was 17.4 (95% confidence interval 16.3 to 18.5) per 100,000 persons per year. There was moderate agreement between the primary prehospital and final hospital diagnoses (Gwet's AC1 coefficient 0.56, 95% confidence interval 0.43 to 0.69). Lack of hospital awareness of the Ambulance continuous positive airway pressure (CPAP): Use, Treatment Effect and economics (ACUTE) trial, limited time to complete trial training and a desire to provide continuous positive airway pressure treatment were highlighted as key challenges by participating clinicians.

LIMITATIONS

During week 10 of recruitment, the continuous positive airway pressure arm equipment boxes developed a 'rattle'. After repackaging and redistribution, no further concerns were noted. A total of 41.4% of ambulance service clinicians not participating in the ACUTE trial indicated a difference between the control and the intervention arm trial boxes (115/278); of these clinician 70.4% correctly identified box contents.

CONCLUSIONS

Recruitment rate was below target and feasibility was not demonstrated. The economic evaluation results suggested that a definitive trial could represent value for money. However, limited compliance with continuous positive airway pressure and difficulty in identifying patients who could benefit from continuous positive airway pressure indicate that prehospital continuous positive airway pressure is unlikely to materially reduce mortality.

FUTURE WORK

A definitive clinical effectiveness trial of continuous positive airway pressure in the NHS is not recommended.

TRIAL REGISTRATION

Current Controlled Trials ISRCTN12048261.

FUNDING

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in ; Vol. 25, No. 7. See the NIHR Journals Library website for further project information.

摘要

背景

急性呼吸衰竭是一种危及生命的紧急情况。标准的院前管理包括控制性氧疗。持续气道正压通气是一种潜在有益的替代治疗方法;然而,尚不确定这种治疗方法是否能改善国民保健制度(NHS)救护车服务的结局。

目的

评估一项大型实用试验的可行性,并更新现有的经济模型,以确定成本效益和进一步研究的价值。

设计

(1)一项开放标签、个体患者随机对照外部先导试验。(2)成本效益和价值信息分析,更新现有的经济模型。(3)辅助子研究,包括急性呼吸衰竭发生率研究、急性呼吸衰竭诊断一致性研究、临床医生对持续气道正压通气混合方法研究的看法以及对分配隐藏的调查。

地点

四家西米德兰兹救护车服务中心,于 2017 年 8 月至 2018 年 7 月期间招募患者。

参与者

纳入有呼吸窘迫和外周血氧饱和度低于英国胸科协会(British Thoracic Society)目标水平的成年人。排除有持续气道正压通气获益有限或有禁忌症的患者。

干预措施

院前持续气道正压通气(O-Two 系统,O-Two Medical Technologies Inc.,安大略省布兰普顿)与英国胸科协会外周血氧饱和度目标的标准氧疗进行比较。干预措施在相同的密封盒中提供。

主要结局测量

可行性目标估计了合格患者的发生率、适当分配和接受治疗的比例、对分配治疗的依从性以及保留和数据完整性。主要临床终点是 30 天死亡率。

结果

共纳入 77 例患者(目标 120 例),其中 7 例患者的诊断表明持续气道正压通气可能无效或有害。74%的参与者接受了持续气道正压通气的完全治疗(目标 75%)。没有重大的方案违规/不合规行为。所有关键结局都有完整的数据(目标≥90%)。30 天死亡率为 27.3%。在 21 名死亡患者中,14 名(68%)要么没有呼吸系统疾病,要么实施了治疗上限决策,排除了医院无创通气和重症监护。基本的经济评估表明,标准氧疗可能具有成本效益(增量成本效益比为每质量调整生命年 5685 英镑),但存在很大的不确定性(人群预期完全信息价值为 1650 万英镑)。部分完全信息分析的预期价值表明,院前持续气道正压通气的有效性是唯一重要的变量。急性呼吸衰竭的发生率为每 10 万人每年 17.4 例(95%置信区间为 16.3 至 18.5)。主要院前诊断和最终医院诊断之间的一致性中等(Gwet's AC1 系数为 0.56,95%置信区间为 0.43 至 0.69)。参与临床医生强调了一些关键挑战,包括医院对救护车持续气道正压通气(CPAP)的使用、治疗效果和经济学(ACUTE)试验的认识有限、完成试验培训的时间有限以及提供持续气道正压通气治疗的愿望。

局限性

在招募的第 10 周,持续气道正压通气组设备箱出现“嘎嘎”声。重新包装和重新分配后,没有发现其他问题。41.4%的未参与 ACUTE 试验的救护车服务临床医生表示,对照组和干预组试验箱之间存在差异(115/278);其中 70.4%的临床医生正确识别了箱内物品。

结论

招募率低于目标,可行性未得到证实。经济评估结果表明,一项确定性试验可能具有成本效益。然而,持续气道正压通气的依从性有限,以及难以确定可从持续气道正压通气中获益的患者,表明院前持续气道正压通气不太可能显著降低死亡率。

未来工作

不建议在国民保健制度中进行持续气道正压通气的确定性临床有效性试验。

试验注册

当前对照试验 ISRCTN84514356。

资金

该项目由英国国家卫生研究院(NIHR)卫生技术评估计划资助,全文将在;第 25 卷,第 7 期。有关该项目的更多信息,请访问 NIHR 期刊库网站。

相似文献

9

本文引用的文献

8
A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest.一项肾上腺素在院外心脏骤停中的随机试验。
N Engl J Med. 2018 Aug 23;379(8):711-721. doi: 10.1056/NEJMoa1806842. Epub 2018 Jul 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验